<DOC>
	<DOCNO>NCT00364195</DOCNO>
	<brief_summary>This Phase II study design evaluate whether co-administration fix dose tesmilifene standard regimen docetaxel alters plasma pharmacokinetics docetaxel . This study also assess safety efficacy tesmilifene/docetaxel combination metastatic breast cancer patient .</brief_summary>
	<brief_title>Tesmilifene Combination With Docetaxel Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description>Primary Objective : 1 . To evaluate whether co-administration fix dose tesmilifene ( 5.3 mg/kg ) standard dose docetaxel ( 100 mg/m2 ) alters plasma pharmacokinetics docetaxel compare pharmacokinetics docetaxel give alone . Secondary Objectives : 1 . To correlate plasma tesmilifene level follow infusion acute tesmilifene-related adverse event observe infusion . 2 . To collect safety information tesmilifene administer combination docetaxel . 3 . To evaluate response rate , duration response overall survival metastatic breast cancer patient receive docetaxel plus tesmilifene .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Tesmilifene</mesh_term>
	<criteria>1 . Patients document histological/cytological proof metastatic and/or recurrent breast cancer suitable treatment docetaxel 2 . Patients must document hormone receptor status ( ER/PR ) Her2 neu status determine either Immunohistochemistry FISH , within 21 day randomisation , possible , otherwise receptor status patient history use , determine earlier biopsy/surgery . Patients may randomise whilst result hormone receptor status ( ER/PR ) Her2 neu status pending laboratory . 3 . Radiological investigation must conduct within 21 day prior randomization . Exceptions make patient NEGATIVE examination 35 day prior randomisation . 4 . Presence least one unidimensional measurable lesion . 5 . Disease free interval ( DFI ) less equal 24 month ( time initial surgery randomization date ) . 6 . Previous hormone therapy , chemotherapy radiation therapy allow define protocol 7 . Patients ECOG status 0 , 1 2 . 8 . Have life expectancy least 6 month 9 . Patients must female age ≥ 18 year ≤ 65 year 10 . Patients must willing able follow instruction make require study visit . 11 . Patients must willing able give write consent participate study . 12 . Patients must adequate organ marrow function define protocol . 13 . All woman childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L BHCG ) within 72 hour prior randomization . 14 . Patients must negative blood test HIV Hepatitis B C within 4 week prior randomisation . 1 . Patients previous malignancy , exclude curatively treat basal squamous cell carcinoma skin insitu cervical cancer cancer treat five year prior study entry presume cure . 2 . Patients know brain meningeal metastasis ( CT scan require rule unless clinical suspicion CNS disease ) . 3 . Patients whose measurable disease bone . 4 . Patients use chemotherapeutic agent malignancy within 4 week prior study entry recover adverse event due agent administer 4 week earlier . 5 . Patients receive treatment investigational drug within precede 4 week . 6 . Patient receive hormone treatment cancer within 6 week 5 halflives enrolment ( whichever short ) . 7 . Pregnant breastfeeding female . 8 . Patients history seizure disorder . 9 . Patients clinically significant cardiovascular , pulmonary , renal , endocrine , hepatic , respiratory , neurologic , psychiatric , immunologic , gastrointestinal , haematologic , metabolic condition laboratory abnormality , opinion Investigator Medical Director YM BioSciences Inc. , make patient unsuitable participation study . 10 . Known allergy hypersensitivity test article ingredient . 11 . Patients COX 1 2 prostaglandin inhibitor ( e.g . ASA , NSAID 's , Celebrex® , Vioxx® ) comply guideline concomitant therapy outline appendix V , i.e . ; avoid midnight treatment midnight post treatment . Patients require take low dose aspirin ( 81 mg ) may allow continue take low dose aspirin . 12 . Patients H1 antagonist ( e.g. , antihistamine , antidepressant antiemetic ) detail appendix V comply guideline concomitant therapy outline appendix V , i.e . ; avoid 12 hour start protocol treatment begin patient protocol treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Tesmilifene</keyword>
	<keyword>DPPE</keyword>
</DOC>